Basal-bolus insulin therapy in Type 1 diabetes: comparative study of pre-meal administration of a fixed mixture of insulin lispro (50%) and neutral protamine lispro (50%) with human soluble insulin

What Was Tested

Researchers studied Insulin Lispro in this randomized controlled trial publication.

Both regimens included bedtime human isophane (NPH) insulin.

Who Took Part

According to the abstract, 109 patients were involved.

By PubMed's age tags, the people studied were adults, both men and women.

This was a multinational, multicentre, randomized, open-label, two-period crossover comparison of two insulin treatments for two 12-week periods in 109 patients with Type 1 diabetes.

How the Study Was Run

In design terms this was a randomized, open-label, crossover and multicenter study.

The patients were allocated by chance, so the Insulin Lispro group and the comparison group should start out alike.

Everyone knew when Insulin Lispro was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

In the crossover set-up each of the patients took both Insulin Lispro and the comparison in turn, acting as their own control.

More than one site took part, so the patients came from several places.

What Was Measured

The subject headings attached to it are Blood Glucose, Circadian Rhythm, Diabetes Mellitus, Type 1, Hypoglycemia, Hypoglycemic Agents, Insulin and Insulin Lispro.

What This Means in Plain Language

The paper is a randomized, open-label and crossover study of Insulin Lispro in 109 patients.

Results are reported in around 8 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2002 (Diabetic medicine : a journal of the British Diabetic Association), a journal based in England.

More context: the Insulin Lispro compound page, all human trials.